Try our Advanced Search for more refined results
Life Sciences - March, 2020
445 articles
- Teva Can't Nix ERISA Suit Over Excessive Fee Allegations
- How COVID-19 Could Spur The Gov't To Seize Patents
- Avet Diabetes Med Contains Carcinogen, Suit Says
- Allergan Defeats Untimely NJ Insurance Fraud Claims
- Indivior Again Fails To Dodge Feds' Opioid Marketing Case
- Gov't Contracts Of The Month: Virus, Wall, Missile Defense
- EpiPen Buyers Can't Inject RICO Suit Into MDL, Court Told
- Ex-Theranos CEO Wants Trial Prep OK'd Amid Pandemic
- Law Firm Pay Cuts, Layoffs Will Likely Multiply
- Amarin's Vascepa Patents Struck Down As Generics Ramp Up
- 9th Circ. Lifts Stay In Soured IVF Center Deal Dispute
- Atty Says Stock Fraud Conviction Based On False Testimony
- Key Takeaways From DOJ's 2019 FCA Recovery Stats
- What FDA Has Done So Far In Response To COVID-19
- FDA Seeks Extension Of Vape App Deadline Due To COVID-19
- Evoqua Must Face Some Investor Claims Over $500M IPO
- 3 Steps To Building Effective Teams While On Lockdown
- Merck Can't Trim Dozens Of Suits From Zostavax MDL
- Health Hires: Arnold & Porter, Winston & Strawn, Ice Miller
- Ra Pharma's $2.1B Sale Teed Up To Close After False Starts
- Genentech Loses Eye-Drug Patent Rights Over Agent's Error
- Cadwalader Cuts Pay Across The Firm To Weather Pandemic
- Tucker Ellis Adds Bankruptcy Partner In Chicago
- Fed. Circ. Won't Stay Arthrex Decision For High Court Appeal
- White House Expects Huge Death Toll As Virus Rages On
- Businesses Urged To Make COVID-19 IP Free During Crisis
- Sen. Floats Bill To Shield COVID-19 Doctors From Legal Action
- 6th Circ. Says Court Had No Jurisdiction In DePuy Hip Suit
- Monsanto Wants To Erase $265M Dicamba Verdict
- CBD Buyers Say They Shouldn't Have To Wait For FDA Action
- Bluebird Bio Directors 'Grossly' Overpaid, Chancery Suit Says
- Anapol Weiss Seeks Much Of $3.8M Sorin MDL Common Fund
- Texas Cos. Look To Block ACA Preventive-Care Mandates
- FTC Fights Surescripts' Bid For DC Circuit Appeal
- Companies Forced To Get Creative As Public Markets Stall
- Some Claims Weeded Out Of CBD False Ad Suit
- Del. Court Says DuPont Can Arbitrate Chemours Suit
- Latham Steers Cancer Therapy Biz In $130M IPO Filing
- US Trustee Says Melinta Plan Releases Go Too Far
- Tips For Cos. Confronting Pandemic Impact On Global Trade
- EU Trade Chief Defends Medical Export Restrictions
- High Court Won't Revive Enzo Suit Over 'Lax' Enablement Test
- Law Firm Mergers Dry Up Due To Coronavirus Pandemic
- Client Advocacy Tips For Remote Hearings During COVID-19
- How To Conduct Depositions Remotely
- Potential Cancer Drugs Licensed In Deal Worth Up To $137M
- COVID-19 Raises Unique Issues For Health, Life Sciences Cos.
- The Attys And Legal Logic Behind Stay-At-Home Orders
- Jushi Can't Stop Harvest's Acquisition Of Fla. Medical Pot Co.
- HHS Can't Appeal True Health Medicare Reimbursement Order
- Insurers Tell Justices Fed. Circ. Rule Will Keep Drug Prices Up
- CBD Co. Can't Shake Topical Cream Maker's Trade Secret Suit
- Lab Demands DOJ Reveal 'Secret' Cannabis Research Policy
- Trump Wields Wartime Law For GM To Make Ventilators
- All Arthrex Parties Back Feds' Stay Bid For High Court Appeal
- A Guide To Zealously Representing Clients During COVID-19
- Intercept Beats Investor Suit Over Liver Disease Drug Deaths
- Pfizer Wins Delay For Expert Busy On Coronavirus Task Force
- States Give Hemp Farmers A New Market In Marijuana Industry
- Coronavirus Q&A: Buchanan Ingersoll's FDA Chair
- Army Correct To Reject Bids From 2 Cos. With Same CEO
- Drug Pricing Legislation In Doubt After COVID-19 Relief Bill
- Fed. Circ. Affirms PTAB Ax Of 2 Cancer Drug Patents
- Meningitis Vaccine Developer Lands $110M In Funding Round
- Genentech Says It Shouldn't Lose Patent Rights Over Error
- Pandemic Won't Stop Arguments In J&J's $4.7B Talc Appeal
- NY AG Warns Air Purifier Sellers To Stop COVID-19 Claims
- G-20 Pledges Only Limited Trade Restrictions Amid COVID-19
- UK Watchdog Probes Elanco's Dog Ear Treatment Deal
- 3rd Circ. Won't Revive Merck Vaccine Suit Over Atty Conduct
- CBP Drops Plan To Delay Tariff Payment During COVID-19
- Trade Group Urges High Court To Bury Arkansas PBM Law
- Convicted Insys Exec Says Forfeiture Unfair In Bear Market
- Abbott Wins Test Strip Suit After Supplier's Discovery Fraud
- AGs Ask Feds To Allow Fetal Tissue Research For COVID-19
- Israel's Generic COVID-19 Drug Licensing Lacks Due Process
- Pandemic Spotlights Opportunistic Product Health Claims
- 7 Ways Attys Can Create The Right Home Office Environment
- Ariad Exec's Spouse Can't Shake Insider Trading Conviction
- After Backlash, Gilead Ditches 'Orphan' Status For Virus Drug
- Fed. Circ. Trims Galderma's Patent Win Over Oracea Generic
- Automakers' Shift To Med Supplies Comes With Legal Hazards
- D.C. Latest to Declare Medical Pot Essential In Outbreak
- Insurer Says No Coverage In Contaminated Melatonin Suit
- Ex-Pot Co. Exec to Mediate Fight Over Acquisition Cash
- Bayer And Novartis Lose Challenge To NHS Eye Drug Policy
- EU Probing J&J's $400M Deal For Takeda's Surgical Patch
- 10 E-Discovery Challenges Caused By COVID-19
- Data Co. Beats PBM's Suit Alleging Foreign Trade Secret Theft
- Jefferies Adds $10M To Federal Drug Packaging Partnership
- Abiomed Escapes FCA Whistleblower's Retaliation Claim
- Trump's Tariff Delay Proposal Draws Fire From US Producers
- Novartis Wants Lupin's Generic Heart Failure Drug Blocked
- COVID-19 As A Material Adverse Change In M&A Agreements
- NJ, Texas Law Firms Beat Suit Over Pelvic Mesh Atty Fees
- Express Scripts Off The Hook For $50M Prescription Drug Bill
- Counsel To Get Up To $93M In Fees In Xarelto MDL
- Chinese Cancer Research Co. Lands $60M Funding
- PTAB Sets More Precedent On Its Discretion To Deny Petitions
- Medical Pot Grower Can't Escape Ex-Partners' Suit
- Class Attys Seek More Than $4M For NantHealth IPO Action
- Fla. AG Targets 43 Vendors For Amazon Price-Gouging Claims
- Boehringer Beats Marketing Software Co. In Conspiracy Trial
- Trade Monitor Urges Lowering Barriers To Aid Virus Response
- Ex-Army Biomedical Engineer Can't Sink Philips NDA Suit
- EpiPen Buyers Tear Into Mylan, Pfizer Bid For Cert. Review
- BigLaw Leaders Must Prepare For COVID-19 Economic Fallout
- Maynard Cooper Nabs IP Litigator From Jones Day
- Edwards' Patent Suit Over Heart Valve Device Set For July Trial
- FEMA To Use Wartime Law To Meet COVID-19 Medical Demand
- Gibson Dunn Nabs Life Sciences Deals Atty From Goodwin
- Walgreens 'Systemically Overcharged' For Drugs, Insurers Say
- CBD Website Escapes Libel Suit Over 'Heavy Metals' Article
- Chinese Hospital Seeks Info On Soured IVF Center Deal
- Justices, Congress Might Tackle PTAB Constitutionality Next
- Opioid Negotiation Class Says It's Not Bound By 'Straitjacket'
- Orthodontist Assoc. Denied Amicus In SmileDirect Suit
- Mallinckrodt Dodges MS Drug Monopoly Suit
- Kappos Says Pandemic Calls For New Medical IP Precedent
- Drug Cos. Want Slow SF Opioid Case Timeline Amid COVID-19
- High Court Turns Down Allergan Breast Implant Suit
- Ex-Theranos Execs Holmes, Balwani To Get Separate Trials
- Open Issues After Fed. Circ. PTAB Judge Appointments Ruling
- Alnylam Dodges Stock-Drop Suit Over FDA Approval Efforts
- Ex-Pharma Exec Seeks Early Prison Exit Over COVID-19 Risk
- 3 Ways Leaders Can Improve Remote Work For Lawyers
- Tips For Online Mediation In The Age Of Social Distancing
- How To Manage Marketing Risks For CBD Products
- Mitsubishi, Janssen Seek To Block Generic Diabetes Drug
- 4 Cases Show Growing Reach Of Federal Fraud Statutes
- Pa. Relaxes Medical Pot Regs Amid Coronavirus Pandemic
- Drug Cos. Say 'Buy US' Order Would Hurt COVID-19 Response
- FTC Data Security Consent Orders Are New But Not Improved
- Ex-USPTO Leader, Oblon Attorney Mossinghoff Dies At 84
- USTR Flooded With Bids For COVID-19 Tariff Waivers
- Full Fed. Circ. Won't Review PTAB Unconstitutionality Case
- A Look Into FTC's Thinking On Pyramid Scheme Potential
- In Faultily Redacted Docs, Attys Say Exec Defrauded CBD Co.
- USTR Weighing China Tariff Cuts To Fight Coronavirus
- Insys Founder Tells 1st Circ. COVID-19 Risk Merits Bail
- Flintstones 'Complete' Vitamins Consumers Seek Class Cert.
- Market Turmoil Begins To Strain Even Blank-Check Deals
- Shkreli-Founded Co. Defends Its Handling Of Life-Saving Drug
- Real Estate Rumors: Deerfield, CGI, National Development
- DEA Pushes Major Increase Of Research Cannabis Cultivation
- Farming, Food Groups Sue EPA Over Glyphosate Approval
- 3 Firms Steer Chinese Pharma Co.'s $288M Hong Kong IPO
- J&J Says Talc Supplier Imerys Doesn't Need More Ch. 11 Time
- Ex-Pfizer Exec Fights Fidelity's Bid To Exit Pension Tax Suit
- Updating Publicly Traded Company Disclosures For COVID-19
- 3D Printing As Indirect Patent Infringement Amid COVID-19
- PTAB Axes Bulk Of Possible Cancer Treatment Patent In PGR
- FDA Tries To Boost Hand Sanitizers Amid COVID-19 Crisis
- Calif. Pay-For-Delay Ban Hurts Pharma Cos., 9th Circ. Told
- How Trump's Wartime Order Affects Medical Manufacturers
- 'Complete Disregard' Of Service Rules Kills Syneos Stock Suit
- Coronavirus-Disrupted Drug Firm's $23M Ch. 11 Sale OK'd
- Genentech Sues Fresenius Kabi Over Generic Cancer Drug
- Japanese Device Co. Must Face FCA Suit Over Medicare Fraud
- PTAB To Review Allergen Juvederm Patent At Heart Of IP Suit
- Nevada Says Pot Shops Can Stay Open Amid COVID-19 Crisis
- Judge Can't Impose Vape Application Deadline, 4th Circ. Told
- Danaher Gets FTC Approval For $21B GE Biopharma Deal
- SEC Settles PetMed Insider Trading Claims For $1.25M
- SmileDirect Complaint Against Calif. Dental Board Trimmed
- FDA Clears Abbott Test For COVID-19
- Mylan, Pfizer Want EpiPen Row Paused For Class Cert. Appeal
- US Trustee's Objections To Valeritas Settlement Resolved
- Investor Says Biotech Co. Blew Drug Approval, Hurting Stocks
- The Rising COVID-19 Bankruptcy Risks
- Ruling In HHS Case May Mean More Drug Trial Reporting
- Israel Defies AbbVie IP To Import Generic Drugs For COVID-19
- WTO Forms Panel To Hear EU-Turkey Drug Production Case
- Trump Races To Boost Health Capacity As Virus Cases Soar
- Judge Won't Pause Investors' Doc Bid For Chinese IVF Fight
- Biogen Sues Over 'Copycat' Alzheimer Treatment Products
- Md. Pot Shops Told To Stop Using 'Sniff Jars' Amid Outbreak
- Sens. Sound Privacy Alarm On Google's Virus Screening Site
- 'Pharma Bro' Suit Proceeds By Phone As COVID-19 Spreads
- Robins Kaplan To Share $2.2M Fee With NJ Solo Atty
- COVID-19 Closures Could Help Illegal Dealers, Pot Groups Say
- Gilead Knowingly Peddled Dangerous HIV Drugs, Suit Says
- Teva Warns Fed. Circ. IP Ruling Has 'Perverse Consequences'
- Purdue, Sacklers Keep Opioid Suit Shield For 6 More Months
- Bayer Asks Ill. Justices To Boot 160 Claims From Essure Suits
- COVID-19 Relief Bill Includes Protections For Face Masks
- First Zofran Bellwether Delayed Indefinitely Due To COVID-19
- Cell And Gene Therapies Are Driving M&A Deal Activity
- FTC Staffers Greenlight Allergan Divestitures In AbbVie Deal
- 7th Circ. Says Judge Wrongly Denied Disability Benefits
- LibbyHoopes Atty's Threat To Priest In SEC Case Irks Judge
- A Work-From-Home Tech Checklist For Law Firms
- Workers Call DST Bid To Boot ERISA Counsel A Delay Tactic
- NECC Execs Push 'Legal Impossibility' Defense In 1st Circ.
- Del. Jurors Clear Oxford Nanopore In DNA Tech Patent Suit
- NY County Fights Mallinckrodt Bid For Separate Opioid Trial
- The Top Coronavirus Questions Health Attys Are Hearing
- Split Fed. Circ. Revives Sequenom Fetal DNA Test Patents
- Medical Pot Deemed 'Essential' Amid COVID-19 Shutdowns
- CBD Producer Wants Out Of Suit Alleging Illegal Product Sales
- Del. Justices Say Partner Swap Kills Whistleblower Standing
- Indivior Rips New Filings In 3rd Circ. Suboxone Antitrust Row
- Glancy Prongay Seeks To Represent Blood Clot Co. Investors
- Feds Say Greenberg Traurig Has Conflict In $1B Fraud Case
- Doc Who Pled Guilty To Pushing Pill 'Goodie Bags' To Pay $3M
- Major Cos. Urge Justices To Hear Generics Discovery Row
- DNA Registry, Sperm Bank Intersection Raises Legal Issues
- Fortress Offers IP Rights To Fight COVID-19 After Backlash
- Venture-Backed Biotech Firm Files $86M IPO In Stalled Market
- SEC Says Fla. Men Traded On PetMed Insider Info
- Risperdal Breast-Growth Trial Won't Go To Pa. Supreme Court
- FDA Finalizes New Cigarette Warning Graphics After Setbacks
- 7 Keys To Keeping Your Firm Inclusive In The Coronavirus Era
- China's Review Of Vertical Mergers Is Instructive For US
- 3 Firms Steer BioPharma's Go-Public With Blank Check Co.
- AGC Launches €240M Offer For Italian Biotech Molmed
- FDA Offers 'Unprecedented' Leeway For Coronavirus Tests
- Class Cert. Extended In Monsanto, BASF Dicamba MDL
- Hemp Co. Says CBD Wares Not 'Illegal,' Just Not Regulated
- Fed. Circ. Revives Boehringer Diabetes Drug Patent
- Drug Wholesalers Look To Derail W.Va. Bellwether Opioid Trial
- Sacklers Say Major Purdue Deal Hinges On Longer Ch. 11 Stay
- Full Fed. Circ. Won't Let Hospira Escape $70M Epogen IP Loss
- The Biggest UK IP Cases To Watch In 2020
- 9th Circ. Says Disney Copyright Accuser Is No Godzilla
- When Coronavirus Hoarding Becomes Trade Policy
- Davis Wright Staffer's Death Not Linked To COVID-19
- Fed. Circ. Lets Stand $268M Award In Hearing Aid IP Fight
- Del. Bankruptcy Court Halts All Non-'Time-Sensitive' Hearings
- Pharmacy Groups Say Scant Facts Doom Pricing Site's Suit
- Tribunal Awaits Judge's Nod On Daiichi Drug Patent Fight
- Conn. Judge Again Finds Pradaxa Claims Preempted
- IVF Investors Want Sanctions In Chinese Hospital Fight
- Quest Can Go After Doctor In Suit Over Cancer Death
- NY County Says Meyer Suozzi Betrayed It In Opioid Case
- FDA Report Brings Hope For CBD Dietary Supplements
- 10 Ways To Continue Biz Development During Coronavirus
- BuzzFeed Sues Slew Of Federal Agencies For COVID-19 Docs
- Melinta Creditor Deal OK Clears Path To Ch. 11 Plan Approval
- Fed. Circ. Revives Jublia IP Over 'Unreasonable' Construction
- Namenda Buyers' Attys Seek $212M From Allergan Deal
- Fed. Circ. Won't Review Inherently Obvious Patent Standard
- Bankrupt Drug Co-Op Can Use Lender Cash As It Seeks Sale
- Inovio Investors Sue After COVID-19 Vaccine Claims Busted
- Wis. AG Says Drugmaker Can't 'Compartmentalize' Cert. Fight
- DC Circ. Signs Off On Serial Exclusivity For Orphan Drugs
- FTC Shouldn't Try To Protect Consumers In Foreign Countries
- Akorn Lands Final OK For $30M Deal Over Failed Merger
- 7 Ethics Considerations For Lawyers Using Lead Generators
- States' Case No Bellwether In Price-Fixing MDL, Teva Says
- US Lifts Tariffs On Chinese Medical Equipment
- 2nd Circ. Grounds Delta Flight Attendant's Sex Bias Suit
- Health Hires: Perkins Coie, Edwards Maxson, Tricida
- Eli Lilly Attys Win £400K Costs In Genentech IP Fight
- Insys Execs Say Virus Could Further Delay Surrender Dates
- Davis Wright Staffer Dies Following Flu-Like Symptoms
- Consumers Claim Diet Supplements Had Deadly Ingredients
- UK Litigation Roundup: Here's What You Missed In London
- Coronavirus: The Latest Court Closures And Restrictions
- Jury Finds CBD Co. Liable In SEC's $4M Illicit Stock Sale Suit
- Clubman Didn't Test Its Talc, VP Admits In Asbestos Trial
- China Housed 28% Of Foreign Cos. Sued By Investors In 2019
- Farmers, Monsanto Urge Dicamba Class Cert. Extension
- NY AG Tells Alex Jones To Stop Selling Fake Coronavirus Cure
- Ohio Gov., AG Unveil Opioid Settlement Framework
- CBD Co. Head Wants Conflicted Attys DQ'd In Stock Suit
- Coronavirus-Disrupted Drug Firm's $12M Ch. 11 Loan Gets OK
- SEC Relaxes Audit Verification Rules On Smaller Companies
- Pharma Group Gets $75M To Further Cancer Drug Research
- 2 Circuit Court Rulings Convolute Class Jurisdiction Outlook
- Deals Rumor Mill: Magic Leap, Tegna, WeDoctor
- Coronavirus Challenges Facing Government Contractors
- WilmerHale Steers Rare-Disease Biotech Through $75M IPO
- House Committee Advances Two VA Cannabis Bills
- Abbott Unit Wins IP Injunction On Rival's Heart Surgery Device
- Hairdressers' Exposure To Talc Went Ignored, Witness Says
- Brown Rudnick Exit Bid Challenged In $300M Malpractice Suit
- Express Scripts Can't Shake Amputee Worker's Injury Suit
- NY AG Issues Notices Targeting Purported Coronavirus Cures
- State Immunity Tops Patent Venue Rules, UT Tells Justices
- Apyx Must Face Suit Over Study Results, Judge Finds
- Marijuana Firms Say License Delay Flouts Fla. Constitution
- NJ Suspends Racing Licenses Of 7 Indicted For Horse Doping
- BASF Wants No More Delays On Dicamba Class Cert. Battle
- Humana Missed Mark On Market In Seizure Drug Suit
- NY AG Throws Support Behind Mallinckrodt $1.6B Opioid Deal
- 7th Circ. Plugs National Consumers Back Into Ill. TCPA Suit
- Juul MDL Complaints Consolidate National E-Cigarette Cases
- New Pipelines Are Needed To Close Law School Diversity Gap
- Cooley Adds Ex-Covington Pro To NY Capital Markets Team
- Chicago's Opioid Bellwether Plan Is 'Unworkable,' Judge Says
- Gilead's Ebola Drug Is Being Used To Treat COVID-19
- 21 Related Teva Price-Fixing Suits Consolidated
- Taro Escapes Off-Label Use Claims For Heart Drug
- Patent Demand Lessons For Cannabis Cos. From Big Tech
- BioPharma Outfit Raises $78.5M To Advance Cancer Therapy
- Feds Eye Tougher Oversight Of Deals Blocking Biosimilars
- Opioid Judge Taps Harvard Prof To Guide $3B Fee Fight
- Perrigo Wins Transfer Of $555M Fraud Suit To NJ
- Expert Tells NJ Jury He Found Asbestos In Clubman Talc
- Justices Urged To Allow Patents For Selective Use Of Meds
- 'Compound King' Convicted In $21M Health Care Fraud Case
- Covidien, Ethicon Revisit IP Rivalry As Device Trial Closes
- Fired NJ Medical Pot User Can Sue Over Disability Bias
- Fed. Circ. Rejects Challenge To 2010 USPTO Patent Term Rule
- Vape Makers Take FDA Challenge To DC Circ.
- BASF, Dow Can't Escape Polyurethane Price-Fixing MDL
- Lessons Learned From Remicade Biosimilar Patent Row
- JLL Partners Joins Medical Industry Veteran In $100M JV
- How To Search For A Transformational Law Firm COO
- Pa. Had No Role In Out-Of-State Mesh Case, Justices Told
- Coronavirus Derails Eagerly Awaited New York Opioid Trial
- Allen & Overy Assists On $600M European Life Sciences Fund
- CMA Sent Back To The Drawing Board In £89M Pfizer Case
- 4 Ethics Tips For Lawyers As Coronavirus Spreads
- 3rd Circ. Signals Disapproval Of Lamictal Antitrust Class Cert.
- Market Turbulence Throws IPO Pipeline Into Question
- Patent Trial Opens Over DNA Tool Used To ID Coronavirus
- ITC To Probe Alleged Infringement Of Nicotine Pouch Patent
- Calif. Appeals Court Upholds Local Ban On Pot Dispensary
- Over 2 Dozen Charged In Alleged Racehorse Doping Schemes
- Surescripts Wants DC Circ. To Review FTC Antitrust Suit
- Judge OKs Par's Settlement In Zetia Pay-For-Delay Case
- Mylan Says Generic Drugs Can't Override IP Venue Law
- FDA Hits Vitamin Co., Televangelist For Fake COVID-19 Cures
- 1-800 Contacts Disputes FTC Found 'Take It Or Leave It' Deals
- FDA Defends Approval Of Genetically Engineered Salmon
- United Opens New Front In Celgene Monopoly Fight
- Top Blockchain Considerations For Health, Life Sciences Cos.
- Keep Your Client Out Of The Courtroom During Voir Dire
- Drug Researcher Charles River Sued For Hiring Activist Spy
- Muscle Milk Maker Reaches $12M Deal To End False Ad Suit
- SEC Says Priest In Fraud Case Threatened Potential Witness
- Curaleaf Looks To Permanently End Investors' Stock-Drop Suit
- 7th Circ. Won't Reinstate $3M Verdict For Reed Smith Widow
- Germ-X Maker Sued Over Coronavirus Protection Claims
- Fed. Circ. Weighs Undoing $268M Verdict Against Cochlear
- Doctors Say No Secret Info Used In FCA Suit Against J&J
- Pot Co. Tilray Hit With Securities Suit After $321M Net Loss
- Asset Mgr. Piles Onto Perrigo Price-Fixing, Securities Claims
- Fed. Circ. Affirms PTAB Save Of Dartmouth Patent Claim
- Assertio, Lupin, Bausch Must Face Buyers' Price-Fixing Suit
- Fed. Circ. Won't Block Amgen's Herceptin Biosimilar
- Winston & Strawn, Loeb & Loeb Steer 2 IPOs Worth $660M
- Cannabis Bill Roundup: Connecticut Talks Legalization
- Suboxone Buyers Fight 3rd Circ. Appeal Of Class Cert.
- Coronavirus-Impacted Drug Firm Gets OK On Ch. 11 Sale Plan
- FDA Focus: What King & Spalding's Practice Head Is Watching
- A Possible Limit On High Court 2005 Agency Deference Ruling
- AARP, Consumer Groups Back Calif. Pay-For-Delay Ban
- Proactiv Producer Says Pharmacies Faked Reimbursements
- J&J Escapes Suit After Couple Can't ID Pelvic Mesh Maker
- Investor Sues Biopharma Co. Over Study Disclosure
- Justices Reverse Alito's Partial Stay Of Generics Discovery
- Steps For Cos. Reacting To Anonymous Short-Seller Claims
- It Can Be Risky For Litigators To Advise On Litigation Funding
- Illinois Brick Doesn't Kill Med Supply Suit, 7th Circ. Says
- Pharma Investor Says $11M Public Offering Breached Contract
- 1-800 Contacts Tells 2nd Circ. FTC Wrongly Barred Ad Deals
- ABA, Health Tech Events Scuttled Amid Coronavirus Fears
- Fed. Circ. Grapples With Double-Patenting In Enbrel Case
- Noncompete Can't Kill Radiology Salesman's Jump To Startup
- Fed. Circ. Doubts Illegality Of USPTO's 2010 Patent Term Rule
- Purdue Wants Ch. 11 To Hold Opioid Cases At Bay Longer
- Fed. Circ. Affirms Celltrion, Hospira Didn't Infringe Janssen IP
- Del. Justices To Weigh In On AmerisourceBergen Doc Fight
- DOJ Urges High Court Not To Eye FCA Dismissal Campaign
- New Jersey Jury Told That Barbershop Talc Caused Cancer
- Feds Say Spine Device Firm Ran $8M Kickback Scam
- 2 Firms Edge Ahead Of Peers In Quiet February For IPOs
- Fed. Prohibition Trumps State Med. Marijuana Law, Utility Says
- Insys Execs Can't Delay Prison In Opioid Kickback Case
- Stop Asking Bar Applicants About Mental Illness
- 3rd. Circ. Doubts Lawsuit Press Release Defamed Pharma Co.
- Celgene Tells Justices Retroactive IPRs Are Unconstitutional
- Anika Therapeutics Hires Insulet, Covidien Alum As GC
- Fed. Circ. Asks If All J&J Units Belong In Remicade IP Fight
- House Greenlights $8.3B For Fighting Coronavirus
- Gilead Can't Duck Sweeping Competition Suit Over HIV Drugs
- 9th Circ. Says Judge Wrongly Put Warning In FDA Complaint
- Fed. Circ. Affirms Automated Eye Exam IP Wasn't Infringed
- Vaccine IP Under Microscope With Coronavirus Outbreak
- Ex-NFL Player Must Undergo Psych Evals In Pain Pump Case
- New York Court Refuses To Delay March Opioid Trial
- Loeb & Loeb Picks Up DLA Piper FDA Team Head In DC
- Topical Cream Maker Fights Dismissal Of CBD Product Suit
- High Court Must Reject Unconstitutional La. Abortion Law
- Gov't Intervention In A Private Civil Suit Can Benefit Defendant
- Teva Wants 'Scattershot' 401(k) Fee Suit Scrapped
- What The Coronavirus Means For Arbitration And Mediation
- NeuroMetrix Settles FTC Suit Over Wearable Devices For $4M
- Fed. Circ. Calls Biotech's Last-Minute Bid An 'Ambush'
- Feds Claim Pharmacists Ran Protein Shake Kickback Scheme
- Enzo Tells Justices Fed. Circ. Set 'Lax' New Enablement Test
- Rival Dental Supplier Slams 2nd Arbitration Bid At High Court
- Cannabis IP Expert Joins Panitch Schwarze
- Tech Developer Says Wage Suit With Pot Co. Belongs in Calif.
- Feds Tell High Court ERISA Doesn't Doom Arkansas PBM Law
- Venture-Backed Imara Primes $76M IPO Amid Volatile Market
- Tracing The Fate Of The Decade's Biggest Patent Verdicts
- Canadian Pot Cos. Settle Joint Venture Ownership Dispute
- Gov't Attys' Conduct In Medical Co. Kickback Suit Deemed OK
- What Congress Misses About Universal Injunctions
- Why I Became A Lawyer: Lessons From 'Italian Summer Camp'
- Foreign Influence Lessons From Research Org FCA Deal
- DOJ Says Mallinckrodt Bilked Medicaid As Drug Price Soared
- Biggest Patent Verdicts Fall To Fed. Circ.'s Ever-Moving Target
- Gunderson Dettmer Reps Hearing Loss Co. On $105M Funding
- CBD Firm Head Says Co. Must Cover Her Stock Suit Defense
- 6 Firms Drive Thermo Fisher's $11.5B Deal For Qiagen
- Investors Say Shire Tried To Spin Free Of $45M Merger Tab
- Pharmacies Say Surescripts Can't Duck Monopolization Suit
- Bayer, Google Among Cos. Urging Change To Expert Standard
- Boston Scientific Blasts $5.5M Atty Fee Award In FCA Suit
- Church & Dwight Must Face False Ad Suit Over Vitamins
- Mass. Judge Refuses To Ban CPAP Cleaner From Expo
- Fed. Circ. Judge Considers Retrying Alere Drug-Test IP Fight
- Rosen Firm Wants To Lead Investor Suits Against Fla. Pot Co.
- USPTO Signals It's Eyeing High Court For Arthrex Progeny
- 46 AGs Back Arkansas In High Court ERISA Preemption Fight
- Ex-USPTO Chief's Testimony Not A 'Waste Of Time,' Court Told
- White & Case Guides $825M Takeda Drug Divestment
- US Chamber Urges Justices To Hear Generics Discovery Issue
- Workers Say Yale's Wellness Policy Violates Bias Laws
- NY Cancer Doc Dodges Prison In Insys Kickbacks Case
- Prepare Your Law Firm Tech For Coronavirus Impact
- Mediators To Form Plan For Purdue Ch. 11 Claims Distribution
- 5th Circ. Clears Walgreens In Amputee's Storefront Crash Suit
- Harsher Terms Nixed For Cases Tainted By Mass. Lab Scandal
- Puma Biotech Can't Upend $22M Loss In Exec's Libel Case
- Atty Tips To Avoid 'Scope Creep' And Malpractice Claims
- Commerce Sets Preliminary Duties On Plastic Sheets
- Goodwin-Steered Akrevia Rebrands, Nabs $100.5M Funding
- Sandoz To Pay $195M For Generic-Drug Antitrust Violations
- Shook Hardy Brings On 4 Goodell DeVries Attys In Philly
- Diagnosing Sales Tax Rules for Digital Health Products
- Hetero, Zydus Settle Novartis MS Drug Suits Before IP Trial
- PharMerica FCA Decision Is A Win For Statutory Interpretation
- AGs Claim Ample Evidence In Generic Drug Price-Fixing Suit
- GSK Settles Anemia Drug Patent Claims On Eve Of Trial
- Slaughter And May Steers Life Science Co.'s $130M Financing
- Medical Device Maker Wants Asset Case Tossed From Philly
- 'Precision Medicine' Raises Complex Legal And Ethical Issues
- Navigating Uncertainty In Digital Health Patent Eligibility
- Skadden, Cooley Guide $4.9B Deal For Cancer Drugmaker